Eli Lilly and Co (LLY) Shares Sold by World Asset Management Inc

World Asset Management Inc trimmed its holdings in Eli Lilly and Co (NYSE:LLY) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,938 shares of the company’s stock after selling 6,706 shares during the quarter. World Asset Management Inc’s holdings in Eli Lilly and were worth $7,512,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Accredited Investors Inc. lifted its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares during the last quarter. Oakworth Capital Inc. lifted its stake in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after buying an additional 20 shares during the last quarter. Sfmg LLC lifted its stake in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after buying an additional 20 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after buying an additional 24 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC lifted its stake in Eli Lilly and by 0.8% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after buying an additional 24 shares during the last quarter. 76.35% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on the company. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday. Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $86.98 to $95.00 in a research note on Tuesday. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Finally, BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 12th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $92.75.

Eli Lilly and Co (NYSE LLY) traded down $0.39 during trading on Friday, hitting $85.82. The stock had a trading volume of 4,445,800 shares, compared to its average volume of 3,173,292. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The stock has a market capitalization of $94,440.00, a PE ratio of 40.87, a PEG ratio of 1.68 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the business earned $0.88 earnings per share. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. sell-side analysts expect that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.62%. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is 99.05%.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock valued at $22,041,236 in the last 90 days. Company insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.truebluetribune.com/2018/01/19/eli-lilly-and-co-lly-shares-sold-by-world-asset-management-inc.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply